Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function
The goal of this pilot study is to effectively treat hypertension in subjects with either known or newly diagnosed hypertension and concurrent evidence of diastolic dysfunction. In patients with predominantly diastolic heart failure it is hypothesized that by using more robust echocardiographic measures of diastolic dysfunction, significant changes will be detected. Furthermore, due to the unique properties of nebivolol it is also hypothesized that there will be improvements in LV function manifesting as increased exercise capacity as well as LVH regression as measured by echocardiography. The investigators hope to reproduce the findings shown in a prior study that showed increased stroke volume and preservation of CO in subjects receiving nebivolol.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function|
- Improvement in LV function. [ Time Frame: Week 2, 4, and Week 10 ] [ Designated as safety issue: Yes ]
|Study Start Date:||November 2009|
|Estimated Study Completion Date:||December 2013|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Starting on 5 mg of Nebivolol then titrated
all subjects will begin an initial dosage of 5mg of Nebivolol titrated (doubling of previous dose) to optimal blood pressure below 130/80 at 2 and 4 weeks after treatment initiation.
Initial dose of 5 mg titrated (doubling of previous dose) to optimal blood pressure.
|United States, Missouri|
|St. John's Mercy Cardiovascular Research|
|St. Louis, Missouri, United States, 63141|
|Principal Investigator:||James A. Stokes, M.D.||St. John's Mercy Heart & Vascular|